Memantine in treatment of OCD

Memantine augmentation of escitalopram in treatment of executive function among patients with OCD, a Double-blind placebo controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211118053093N5

Enrollment

Registered

2023-06-25

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Control group: In the control group, escitalopram starts with a dose of 5 mg per day and after 4 weeks the dose is increased to 10 mg per day and continues this way until the end of 16

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: OCD diagnosis based on DSM-V criteria Y-BOCS score equal or more than 18

Exclusion criteria

Exclusion criteria: Drug abuse Pregnancy Medical problems

Design outcomes

Primary

Measure	Time frame
Yale-Brown Obsessive Compulsive Scale score. Timepoint: Week 0, 4, 8 ,12, and 16. Method of measurement: Yale-Brown Obsessive Compulsive Scale questionnaire.;Barkley Deficits in Executive Functioning Scale score. Timepoint: Week 0 and 16. Method of measurement: Barkley Deficits in Executive Functioning Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Razeghian Jahromi

Shiraz University of Medical Sciences

leilarazeghian1366@gmail.com+98 71 3260 5701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026